BSX - Abiomed: Recovery Mode Has Been Activated - Reiterate Buy Rating

• Abiomed has commenced its path to recovery on the charts, following a big hit in April this year.
• Key tension points for ABMD's share price lie in its Impella sales volume, which continues to gain traction sequentially as we walk through this year.
• Shares are trading at a premium to historical averages and to the peer group, thus balancing the investment case.
• Nonetheless, we are bullish on ABMD shares and see an investment debate that is skewed in investors' favour.
• Here, we present all of the necessary moving parts in the investment debate for the benefit of investors' own reasoning.

For further details see: